101 – 110 of 203
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Trends in dialysis modality choice and related patient survival in the ERA-EDTA Registry over a 20-year period
(
- Contribution to journal › Article
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article
-
Mark
Long-term kidney transplant outcomes in primary glomerulonephritis : Analysis from the ERA-EDTA registry
(
- Contribution to journal › Article
-
Mark
IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2015
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article
-
Mark
BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients.
(
- Contribution to journal › Article
-
Mark
Circulating microRNA expression pattern separates patients with anti-neutrophil cytoplasmic antibody associated vasculitis from healthy controls.
(
- Contribution to journal › Article
-
Mark
Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden.
(
- Contribution to journal › Article
-
Mark
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
Increased levels of neutrophil extracellular trap remnants in the circulation of patients with small vessel vasculitis, but an inverse correlation to anti-neutrophil cytoplasmic antibodies during remission.
(
- Contribution to journal › Article